|Bid||7.00 x 800|
|Ask||7.47 x 1400|
|Day's Range||6.88 - 7.16|
|52 Week Range||6.25 - 10.05|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.94|
The underwhelming share price performance of CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) in the past three years would...
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that Amy Peterson, M.D., chief development officer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 3rd at 2:00 p.m. ET. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. A live webcast of the fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. An archived replay will be available for 30 days following the event. About CytomX TherapeuticsCytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb. Probody therapeutics are conditionally activated biologics designed to remain inactive until they are activated by proteases in the tumor microenvironment. As a result, Probody therapeutics are intended to bind selectively to tumors and decrease binding to healthy tissue, to minimize toxicity and potentially create safer, more effective therapies. As leaders in the field, our innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential first-in-class therapeutic candidates against novel, difficult to drug targets and potential best-in-class immunotherapeutic candidates against clinically validated targets. The CytomX clinical-stage pipeline comprises five assets, four of which are in Phase 2 clinical studies. First-in-class product candidates against previously undruggable targets include a CD166-targeting conditionally activated antibody-drug conjugate wholly owned by CytomX (praluzatamab ravtansine, CX-2009) and a CD71-targeting conditionally activated antibody-drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody-drug conjugates due to their presence on many healthy tissues. The CytomX clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probodies, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). For additional information about CytomX Therapeutics, visit www.cytomx.com and follow us on LinkedIn and Twitter. Probody is a U.S. registered trademark of CytomX Therapeutics, Inc. CytomX Contact:Chau Cheng, PhD MBAVP, Investor Relations & Corp. Communicationsccheng@cytomx.com Direct: (650) 273-4999 Investor and Media Contact:Stern Investor RelationsStephanie Ascherstephanie.email@example.com 212-362-1200
If you want to know who really controls CytomX Therapeutics, Inc. ( NASDAQ:CTMX ), then you'll have to look at the...